China Biopharmaceuticals Holdings' Subsidiary Enshi Pharmaceuticals Wins Two Industry Awards

China Biopharmaceuticals Holdings
2007-03-07 21:19 749

Our Hepatitis drug, Ganbifu, Named as One of China's 2006 "Top Ten Most Popular Hepatic Drugs"

Enshi's General Manager, Peixiang Cong, Honored as One of China's 2006 "Outstanding Managers for Brand Promotion"

BEIJING, March 7 /Xinhua-PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP), a leading Chinese pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced that its subsidiary, Enshi Pharmaceuticals, based in Shenyang, China, has received two industry awards.

China Biopharmaceuticals Holdings' Chairman and Chief Executive Officer Chris Mao said, "On behalf of our company, we congratulate Enshi Pharmaceuticals and its General Manager Peixiang Cong for these honors. We are very proud of our strategy of integrating R&D, production and marketing approach. Enshi has certified GMP production facilities and over 300 employees working to manufacture and distribute over 120 prescription-based and over-the-counter generic Western and Traditional Chinese Medicines drugs in China."

Our Hepatitis drug, Ganbifu, Named One of China's 2006 "Top Ten Most Popular Hepatic Drugs" according to public media such as People's Daily and China United Business and authorized institutions such as China International Brand Academy, and World First Research Center.

Mr. Peixiang Cong, General Manager of Enshi Pharmaceuticals, was honored as one of China's 2006 "Outstanding Managers for Brand Promotion". This award is in recognition of managerial excellence. Mr. Cong was appointed by the company as general manager at Enshi Pharamceuticals after the company's acquisition of Enshi. The honor was bestowed upon Mr. Cong and nine other recipients in the Great Hall of the People in Beijing, China. One hundred leading professionals were selected for the 2006 China Talents Award across 10 different categories ranging from innovation, science and technology, industry and commerce, to management and education.

About China Biopharmaceuticals Holdings

China Biopharmaceuticals Holdings, Inc (Symbol: CHBP) is a vertically integrated pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CHBP's product portfolio includes 260 drugs already approved for manufacturing and marketing by the Chinese State Food and Drug Administration (SFDA). CHBP also has submitted 15 drug applications to the SFDA for its review during the calendar year of 2006. CHBP is a U.S.-listed public company with operating subsidiaries and senior management based in China. For further information, please visit our website at .

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Chris Peng Mao, CEO

China Biopharmaceuticals Holdings

Tel: +86-10-8525-1616



Alan Sheinwald, Partner

HCI Emerging Growth

Tel: +1-914-669-0222


Source: China Biopharmaceuticals Holdings